Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Date:2/5/2008

Mylan to Present at Merrill Lynch's Global Pharmaceutical Conference Feb.

5, 2008

PITTSBURGH, Feb. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarter and nine months ended Dec. 31, 2007. The Company also will provide an operational and integration update on Merck Generics, which the Company acquired on Oct. 2, 2007. The Company will release its financial results before the market opens.

The Company also announced that it will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference today, Feb. 5, at 11:40 a.m. ET. A copy of the Company's slide presentation will be available at http://www.mylan.com.

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325- 4814 for international callers. A replay, available for approximately eight days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfo
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
3. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
4. Mylan Sets Date of 2008 Annual Meeting
5. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
6. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
7. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
8. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
9. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
10. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
11. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 1Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 2Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 1Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 1Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 4